In vivo detection of ifosfamide by 31P-MRS in rat tumours: Increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas

British Journal of Cancer

Volumn 75, Issue 1, 1997, Pages 62-68

  Rodrigues, L M ^a   Maxwell, R J ^b   McSheehy, P M J ^a   Pinkerton, C R ^c   Robinson, S P ^a   Stubbs, M ^a   Griffiths, J R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

31P magnetic resonance spectroscopy; Carbogen; Chemotherapy; Ifosfamide; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOGEN; IFOSFAMIDE; METHYLNITROSOUREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROLACTINOMA; RAT;

EID: 0031031572     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.10     Document Type: Article

References (38)

1. Allen LM, Creavan PJ and Nelson RL (1976) Studies on the human pharmacokinetics of isophosphamide (NSC 109724) Cancer Treat Rep 60: 451-458
2. 13C labelled anticancer agent temozolomide detected in vivo by selective cross polarization transfer. Magn Reson Med. 34, 338-342
3. Benedict FG (1934) Die oberflachen bestimmung verschiedener tiergattungen. Ergeg Physiol, 36, 300-346
4. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ and Idle JR (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 53, 3758-3764
5. Boal JH, Ludeman SM, HO C-K, Engel J and Niemeyer U (1994) Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy. Arzneim-Forsch/Drug Res 44 (1): 84-93
6. 31P NMR spectroscopic observation of the intracellular transformation of oncostatic cyclophosphamide metabolites. J Med Chem 29, 1206-1210
7. Clarke L and Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalyst of drug activation. Cancer Res 50, 4991-5002
8. 31P NMR investigations of phosphoramide mustard: evaluation of pH control over the rate of intramolecular cyclization to an aziridinium ion and the hydrolysis of this reactive alkylator. J Med Chem 22, 897-899
9. 2 histography. Br J Cancer 66, 919-924
10. Gilard V, Malet-Manino MC, de Forni M, Niemeyer U, Ader JC and Martino R (1993) Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorous-31 nuclear magnetic resonance spectroscopy. Cancer Chemother Pharmacol 31, 387-394
11. Goren MP, Wright RK, Pratt CB and Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2, 1219-1220
12. HE Q, Bhujwalla ZM, Maxwell RJ, Griffiths JR and Glickson JD (1995) Proton NMR observation of the antineoplastic agent iproplatin in vivo by selective multiple quantum coherence transfer (Sel-MQC). Magn Reson Med 33, 414-416
13. Honess DJ and Bleehen NM (1995) Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer 72, 1175-1180
14. Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, Denecke H, Berger H, Peter K and Wilmanns W (1990) Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. J Clin Oncol 8, 1818-1829
15. Kaijser GP, Beijnen JH, Bult A and Underberg WJM (1994) Ifosfamide metabolism and pharmacokinetics (Review). AntiCancer Res 14, 517-532
16. 31P NMR spectroscopy. Proc Soc Magn Reson 2nd Meeting, 1317
17. 2 at atmospheric pressure. Cancer 20, 51-58
18. Lind MJ, Margison JM, Cerny T, Thatcher N and Wilkinson PM (1989) Comparitive pharmacokinetics and alkylating activity of fractionated intravenous and oral IF in patients with bronchogenic carcinoma. Cancer Res 49, 753-759
19. Malet-Martino MC and Martino R (1992) Magnetic Resonance Spectroscopy: a powerful tool for drug metabolic studies. Biochimie 74, 785-800
20. 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 260, 1133-1144
21. Murray GI, Weaver RJ, Paterson PJ, Ewem SWB, Melvin WT and Burke D (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169, 347-353
22. Ordidge RA, Connelly A and Lohman JAB (1986) Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 66, 283-294
23. Pinkerton CR and Pritchard J (1989) A phase 11 study of ifosfamide in paediatric tumours. Cancer Chemother Pharmacol 24 (suppl.): 13-15
24. Pratt CB, Douglass EC and Etcubanas EL (1989) Ifosfamide in paediatric malignant solid tumours. Cancer Chemother Pharmacol 24 (suppl.): 24-27
25. 31P NMR. Proc Natl Acad Sci USA 80, 2748-2751
26. Prysor-Jones RA and Jenkins JS (1981) Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in rat. J Endocrinol 88, 463-469
27. Robinson SP, Howe FA and Griffiths JR (1995) Noninvasive monitoring of carbogen-induced changes in tumour blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 32, 855-859
28. Rojas A (1991) Radiosensitization with normobaric oxygen and carbogen. Radioth Oncol 20 (suppl.): 65-70
29. Skinner R., Pearson ADJ., Price L.. Coulthard MG and Craft AW (1990) Nephrotoxicity after ifostamide. Arch Dis Child 65, 732-738
30. Sladek N (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37, 301-355
31. 31P MR studies. Biochiem Biophys Acta 1052, 36-41
32. Taylor NJ, Griffiths JR, Howe FA, Saunders MI, Robinson SP, Thoumine M, Caine LA, Hoskin PJ, Powell M, Chaplin DJ and Baddeley H (1996) Carbogen-induced oxygenation and blood flow changes within human tumours. monitored by Gradient Echo Magnetic Resonance Imaging. Proc Int Soc Magn Reson Med 2:1313
33. 31P MRS: absolute concentrations, signal to noise and prior knowledge. NMR Biomed 8, 87-93
34. 31P NMR signals using the varible projection method and prior knowledge. Magn Reson Med 6, 92-98
35. Vaupel P, Kallinowski F and Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res 49, 6449-6465
36. Wagner T, Heydrich D, Jork T, Voelcher G and Hohorst HJ (1981) Comparitive study of activated ifostamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100, 95-104
37. Wiedemann GJ, Siemens HJ, Mentzel A, Biersack A, Wossmann W, Knocks D, Weiss C and Wagner T (1993) Effects of temperature on the therapeutic efficacy and pharmacokinetics of ifosfamide. Cancer Res 53, 4268-4272
38. Williams JC, Gusterson B, Humphreys J, Monaghan P, Coombes RC and Rudland PS (1985) Isolation and characterisation of clonal cell lines from a transplantable metastasizing rat mammary tumour, TR2CL. J Natl Cancer Inst 74: 415-128